Cover Image
市場調查報告書

藥物輸送:革新&趨勢、醫藥品經營者的影響

Drug Delivery - Innovations, trends, and their impact on pharma

出版商 FirstWord 商品編碼 351698
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
藥物輸送:革新&趨勢、醫藥品經營者的影響 Drug Delivery - Innovations, trends, and their impact on pharma
出版日期: 2015年11月01日 內容資訊: 英文
簡介

本報告以藥物輸送相關最新的革新&趨勢主要相關經營者的專家為對象調查,提供藥物遞輸系統的成長機會,各種解決方案,課題等彙整資料。

主要的調查項目

  • 主要的推進因素、各種設備的市場轉變
    • 口服藥
    • 吸入器
    • 注射設備
    • 貼片
    • 皮下植入
    • 神經刺激設備
    • 智慧裝置
  • 恰當的調劑和輸送系統的開發及選擇的課題
    • 生物醫藥品
    • 生物製藥
    • 賦形劑
    • 大分子、小分子
    • 蛋白質
    • 生技仿製藥
  • 全球的商品化的課題
    • 對企業的地區性法律規章的因應策略
  • 患者配合度的改善與良好的預後
    • 部分系統提供的居家照護的可能性
  • 臨床試驗開始前克服技術課題的意義
  • 各種開發模式的成本效益的檢驗
    • 外包
    • 聯盟
    • 公司內部開發
  • 醫療經濟的藥物遞輸市場革新的影響
    • 償付上的課題
    • 獲得上的課題
目錄
Product Code: 596200371

Why you need Drug Delivery - Innovations, trends, and their impact on pharma

Revolutionary changes are disrupting the status quo simply through developments in the way drugs are given to patients. In a rapidly evolving field, drug delivery systems are offering growth opportunities and solutions - as well as presenting difficulties - as the range of choices grows.

To make sure you don't get left behind you need to understand what is happening at the cutting edge from experts innovating and leading the way through the technological and regulatory minefield. See how companies like Sanofi, Surefire Medical and Invion among other market leaders explain how they see the market and how they are dealing with the challenges.

Top Takeaways:

  • Change is accelerating. There's a wide range of new products at late-stage development, 200+ partnership deals are signed each year and device companies are now entering the market directly
  • Reliance on delivery mechanisms is increasing as health economics requirements on efficacy and cost-effectiveness multiply
  • Significant delivery mechanism opportunities still exist with the potential to solve unmet needs with new formulations
  • Drug combinations offer risks and rewards - the promise of innovative formulas is potentially hampered by technology and regulation
  • Product franchises are protected by differentiating products and by extending a profitable drug's lifecycle
  • Opportunities are growing in new markets as the Far East opens up and China expands healthcare to the wider population

Key Issues Explored

  • Key drivers and how devices are transforming the market including oral medicines, inhalers, injectable devices, patches, subdermal implants, neurostimulation and smart devices
  • The challenges faced in choosing and developing the right delivery system and formulations, looking at biopharmaceuticals, biologics, excipients, large and small molecules, peptides, proteins and biosimilars
  • Hurdles to commercialisation globally - how companies are evolving strategies to deal with local regulatory issues for global products
  • Improving patient compliance with better outcomes and the potential for home-based care offered by some systems
  • The value of overcoming technical challenges before clinical trials begin
  • The cost-benefit considerations of different development models including outsourcing, partnerships and internal development.
  • The impact of health economics on innovation in the drug delivery market, reimbursement concerns and access issues

Who needs this report?

  • Presidents and VPs of product development - to see the drugs and devices in the pipeline and the potential opportunities and risks involved
  • Business development directors - to get support and improve and refine strategic direction and decisions
  • Device development team managers - to see expansion possibilities and the current state of the competitive market
  • Delivery and formulation specialists - to analyse current best practice
  • Manufacturers of devices - to see the top drug delivery partnerships and get an overview of growth prospects
  • Insurers and payers - to gain insights into the value of more effective delivery mechanisms to ensure the best use of limited resources
  • Big data companies and electronic health companies - to see current and future developments in connected devices

Contributors

  • Director, Drug Delivery Technologies, European Pharma Company,
  • Vice President, Medical Device Development, Global pharma Company
  • Igor Gonda: President & CEO, Aradigm Corporation [Linkedin]
  • Jeff Macdonald: Senior Director, Corporate Communications, Acorda Therapeutics
  • Seth Yakatan: CSO, Vice President of Business Development, Invion Group
  • Director, Corporate Development, Respiratory Product Development Company
  • Director, Pharmaceutical Sciences, Respiratory Product Development Company Douglas Marenzi: CEO, PHC Technologies
  • David Urquhart: Business Development, PHC Technologies
  • Morten Nielsen: CEO, Medicom Innovation Partner
  • Frédéric Gabriel: CSO and General Manager, Haselmeier
  • Jim Chomas Ph.D: President and CEO, Surefire Medical
  • Norman Weldon: Chairman, SureFire Medical
  • Julian Chick, Ph.D: COO, Admedus Ltd
  • JP Errico, Ph.D: CEO, electroCore Medical

Table of Contents(SAMPLE)

Executive Summary

Research Objectives

Setting the scene

  • Over a third of approved drugs rely on advanced drug delivery systems
  • Advanced drug delivery solutions at the heart of drug development
  • Oral delivery the number one route of delivery
  • Injectables remain the main route for biopharmaceuticals
  • Significant investment activity in diseases and CNS
  • Single inhaler combination devices expand utility and keep generics at bay

Role of drug delivery

  • Key insights
  • Drug delivery technologies have transformed medicine
  • Deliviery driven by pharma
  • Role 1: Improve patient adherence and compliance
  • Role 2: Improve product lifecycle management
  • Role 3: Increase market access

Challenges of developing drug combin

  • Key insights
  • Regulatory challenges
  • Health economics
  • Technical challenges

Recent innovations in Drug Delivery

  • Key insights
  • Non-injectable biopharmaceuticals take centre stage
  • Next step pulmonary delivery of proteins
  • Smart inhalers improve patient compliance

Co-development of drug devices

  • Key insights
  • Three pronged approach to drug development
  • Companies have to take risks to innovate
  • Partnerships are a two way street

Future opportunities

  • Key insights
  • Connected devices add value
  • Self-regulating devices control long-term release
  • Non-invasive devices address unmet needs

Conclusions

Appendix

Back to Top